AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
procainamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Class I antiarrhythmics, procainamide and lidocaine derivatives | 2270 | 51-06-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | O |
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 2 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 67 % | Benet LZ, Broccatelli F, Oprea TI |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 81 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 212.47 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 83 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.10 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.872 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.893 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 3.648 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 6.252 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 89.830 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 79.140 | % | High | 1 |
| herg | hERG pIC50 | 4.177 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.992 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.373 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 88.070 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 | 71 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GAK,GRK2,GRK3,MAPK7,MARK4,NUAK1,PRKCD,SGK1,SIK2,SIK3,STK33,TEK,TTK,ULK1,ULK2 | 26 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.130 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 52.360 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 93.560 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.574 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 | |
| pppb | Pig plasma protein binding (% unbound) | 90.790 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 26.182 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 91.300 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 83.560 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 864.968 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 2, 1950 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 138.07 | 76.36 | 64 | 160 | 630133 | 41990978 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gliosis | 111.37 | 91.72 | 16 | 836 | 716 | 110587731 |
| Ovarian failure | 106.77 | 91.72 | 16 | 836 | 960 | 110587487 |
| Polyserositis | 105.84 | 91.72 | 16 | 836 | 1018 | 110587429 |
| Premature menopause | 105.72 | 91.72 | 16 | 836 | 1026 | 110587421 |
| Pouchitis | 101.03 | 91.72 | 16 | 836 | 1381 | 110587066 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BA02 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ia |
| FDA EPC | N0000175426 | Antiarrhythmic |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:38633 | sodium channel blocker |
| CHEBI has role | CHEBI:50427 | platelet aggregation inhibitor |
Related Drugs by ATC class:
C01BA Antiarrhythmics, class Ia 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Life-Threatening Ventricular Tachycardia | indication | ||
| Bundle branch block | contraindication | 6374002 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Complete atrioventricular block | contraindication | 27885002 | |
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Prolonged QT interval | contraindication | 111975006 | |
| Second degree atrioventricular block | contraindication | 195042002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Procainamide Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.0 | acidic |
| pKa2 | 8.94 | Basic |
| pKa3 | 2.36 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel alpha subunit | Ion channel | BLOCKER | CHEMBL | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 3.86 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.81 | PDSP | |||||
| Acetylcholinesterase | Enzyme | Ki | 6 | WOMBAT-PK | |||||
| DNA (cytosine-5)-methyltransferase 3B | Enzyme | WOMBAT-PK | |||||||
| DNA (cytosine-5)-methyltransferase 3A | Enzyme | WOMBAT-PK | |||||||
| DNA (cytosine-5)-methyltransferase 1 | Enzyme | WOMBAT-PK | |||||||
| Acetylcholinesterase | Enzyme | Ki | 6 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019904 | VUID |
| N0000147989 | NUI |
| D00477 | KEGG_DRUG |
| 614-39-1 | SECONDARY_CAS_RN |
| 4017622 | VANDF |
| 4019904 | VANDF |
| C0033216 | UMLSCUI |
| CHEBI:8428 | CHEBI |
| CHEMBL640 | ChEMBL_ID |
| DB01035 | DRUGBANK_ID |
| CHEMBL605 | ChEMBL_ID |
| D011342 | MESH_DESCRIPTOR_UI |
| 4913 | PUBCHEM_CID |
| 4811 | IUPHAR_LIGAND_ID |
| 4179 | INN_ID |
| L39WTC366D | UNII |
| 155056 | RXNORM |
| 5358 | MMSL |
| 6415 | MMSL |
| 792 | MMSL |
| d00075 | MMSL |
| 000622 | NDDF |
| 004481 | NDDF |
| 11959009 | SNOMEDCT_US |
| 25254000 | SNOMEDCT_US |
| 372589008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1902 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-900 | INJECTION | 500 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-901 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-322 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 23 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-323 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | ANDA | 23 sections |
| PROCAINAMIDE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1334 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 13 sections |
| PROCAINAMIDE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1392 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 13 sections |
| PROCAINAMIDE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1630 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 65145-155 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 65145-156 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 68083-603 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 68083-604 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4208 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7113 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7115 | INJECTION | 1000 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7170 | INJECTION | 1000 mg | INTRAVENOUS | ANDA | 22 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7353 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 23 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76329-3399 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 84549-399 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |